恒瑞医药：长期管线储备丰厚，短期新药销售放量

Vi e w p o i n t | 12 Jan 2026 01:00:00 ET │ 14 pages Jiangsu Hengrui Pharmaceuticals (1276.HK) Deepest pipeline for long term; new drug sales taking off for near term CITI'S TAKE Why buy Hengrui at this time? —Short term: 1) Accumulated the highest number of new drug launches in 23-25 – expect fast ramp up in 26 with potential for upside surprise (Fig 1); 2) Previously guided but unspecified BD transaction in 2026 can bring upside surprise (Fig 2); 3) 2026 readouts and potential global trials (LP(a) and PD ...